@article{c0a2b34105ec4d4ca80766946b740632,
title = "Exposure to TNF inhibitors is rare at MOGAD presentation",
keywords = "Adverse event, Demyelination, MOGAD, Myelin oligodendrocyte glycoprotein, Tumor necrosis factor",
author = "Vyanka Redenbaugh and Flanagan, {Eoin P.} and Valentina Floris and Pietro Zara and Bhatti, {M. Tariq} and Francisco Sanchez and Matthew Koster and Sara Mariotto and Pittock, {Sean J.} and Chen, {John J.} and Alberto Cauli and Paolo Solla and Elia Sechi",
note = "Funding Information: Eoin P. Flanagan – Dr Flanagan has served on advisory boards for Alexion, Genentech and Horizon Therapeutics. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr Flanagan has received funding from the NIH (R01NS113828). Dr Flanagan is a member of the medical advisory board of the MOG project. Dr Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. ",
year = "2022",
month = jan,
day = "15",
doi = "10.1016/j.jns.2021.120044",
language = "English (US)",
volume = "432",
journal = "Journal of the neurological sciences",
issn = "0022-510X",
publisher = "Elsevier",
}